2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

4:30PM-6:00PM: Abstract Number: 1942

Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus Associate with Decreased White Matter Integrity and Impaired Spatial Memory

4M107 ACR Abstract: SLE–Clinical II: Renal & Neuropsychiatric Disease in SLE (1941–1945)

4:30PM-6:00PM: Abstract Number: 1943

Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort

4M107 ACR Abstract: SLE–Clinical II: Renal & Neuropsychiatric Disease in SLE (1941–1945)

4:30PM-6:00PM: Abstract Number: 1908

Bariatric Surgery Does Not Affect the Incidence of Rheumatoid Arthritis in Obese Subjects

4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

4:30PM-6:00PM: Abstract Number: 1894

Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial

4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

4:30PM-6:00PM: Abstract Number: 1948

Beliefs and Preferences for Reducing Sedentary Time in Those with Current or Past Knee Symptoms

4M117 ARHP Abstract: Pain, Anxiety, & Depression–ARHP I (1946–1951)

4:30PM-6:00PM: Abstract Number: 1915

Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement

4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

4:30PM-6:00PM: Abstract Number: 1946

Changing the Conversation about Pain: Development and Testing of an Interprofessional Pain CME Applicable for Rheumatologists and Rheumatology Health Professionals

4M117 ARHP Abstract: Pain, Anxiety, & Depression–ARHP I (1946–1951)

4:30PM-6:00PM: Abstract Number: 1922

Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain

4M103 ACR Abstract: Pain Mechanisms–Basic & Clinical Science (1917–1922)

4:30PM-6:00PM: Abstract Number: 1956

Cohort Effects in Back Pain: The Effect of Changes in Life-Style and Co-Occurring Conditions

4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957)

4:30PM-6:00PM: Abstract Number: 1932

Complications Following Total Knee Arthroplasty in Inflammatory Versus Osteoarthritis

4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

4:30PM-6:00PM: Abstract Number: 1918

Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients

4M103 ACR Abstract: Pain Mechanisms–Basic & Clinical Science (1917–1922)

4:30PM-6:00PM: Abstract Number: 1947

Do Changes in Pain Sensitization and Depressive Symptoms Mediate the Effect of Extreme Weight Loss on Knee Pain Improvement?

4M117 ARHP Abstract: Pain, Anxiety, & Depression–ARHP I (1946–1951)

4:30PM-6:00PM: Abstract Number: 1927

Do Remission and Low Disease Activity State Go Hand in Hand with Patient’s Perception of Disease Burden and Quality of Life in Systemic Lupus Erythematosus?

4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

4:30PM-6:00PM: Abstract Number: 1944

Does Renin Angiotensin System Blockade in Addition to Immunosuppressive Therapy Improve Proteinuria in Acute Lupus Nephritis?

4M107 ACR Abstract: SLE–Clinical II: Renal & Neuropsychiatric Disease in SLE (1941–1945)

4:30PM-6:00PM: Abstract Number: 1899

Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis

4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].